Human orthopneumovirus
| Azithromycin | RSV | — | Phase 3 | — | Human (multiple) | |
| Ribavirin | RSV | Nucleoside inhibitor; Guanosine (ribonucleic) analog | FDA approved | FDAJapanChinaRussia | Viral RNA pol | |
| EDP-938 | RSV | — | Phase 2 | — | — | |
| Lumicitabine | RSV | — | Phase 2 | — | — | |
| Ziresovir | RSV | — | Phase 3 | — | — | |
| Presatovir | RSV | — | Phase 2 | — | — | |
| PC786 | RSV | — | Phase 2 | — | — | |
| RV521 | RSV | — | Phase 2 | — | — | |
| 4'-Fluorouridine | RSV | Ribonucleoside analog | Preclinical | — | Viral RNA pol | |
| AVN-944 | RSV | IMPDH inhibitor | Preclinical | — | Human IMPDH | |
| Berberine | RSV | AMP-activated protein kinase (AMPK) activator | Preclinical | — | Unknown | |
| Bortezomib | RSV | Proteasome inhibitor (26S subunit) | Preclinical | — | Human proteasome | |
| Clarithromycin | RSV | Prevent viral entry | Phase 2 | — | Human ion channel | |
| Docosanol | RSV | Inhibition of fusion | Preclinical | — | Viral glycoprotein | |
| Fenretinide | RSV | Unclear | Preclinical | — | Human RAR | |
| Lovastatin | RSV | HMG-CoA reductase inhibitor | Preclinical | — | Human HMGCR | |
| Merimepodib | RSV | IMPDH inhibitor | Preclinical | — | Human IMPDH | |
| Monensin | RSV | — | Preclinical | — | Unknown | |
| Mycophenolic acid | RSV | Inosine monophosphate dehydrogenase inhibitor | Preclinical | — | Human IMPDH | |
| Niclosamide | RSV | Unknown | Preclinical | — | Human (multiple) | |
| Nitazoxanide | RSV | Pyruvate inhibitor | Preclinical | — | Human pyruvate synthase | |
| Quercetin | RSV | Inhibition of entry | Preclinical | — | Human (multiple) | |
| Remdesivir | RSV | Viral RNA polymerase inhibitor | Approved (other) | Japan | Viral RNA pol | |
| Resveratrol | RSV | Multiple | Preclinical | — | Human multiple; Viral transcriptional regulator | |
| Salinomycin | RSV | Ionophore | Preclinical | — | Human (multiple) |